Topics
Gliomas | Treatment | Targeted therapy | IDH inhibitors
Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > IDH inhibitors
Ser
MH, Webb M, Thomsen A, Sener U.
Isocitrate
Dehydrogenase Inhibitors in Glioma: From Bench to Bedside.
Pharmaceuticals
(Basel).
2024 May 26;17(6):682. doi:
10.3390/ph17060682. PMID:
38931350.
Review. ˍ
van
den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM,
Young RJ, Pallud J, von Deimling A, Sahm F, Figarella Branger D,
Huang RY, Weller M, Mellinghoff IK, Cloughsey TF, Huse JT, Aldape
K, Reifenberger G, Youssef G, Karschnia P, Noushmehr H, Peters KB,
Ducray F, Preusser M, Wen PY.
The
biological significance of tumor grade, age, enhancement and
extent of resection in IDH mutant gliomas: how should they inform
treatment decision in the era of IDH inhibitors? Invited review.
Neuro
Oncol.
2024 Jun 24:noae107. doi:
10.1093/neuonc/noae107. PMID:
38912846. Review.
ˍ
Still MEH, Moor RSF, Ghiaseddin AP, Leibetseder A, Hottinger AF,
Berghoff A, Leung D.
How do I
prescribe and manage mIDH inhibitors in patients with IDH-mutant
glioma?
Neurooncol
Pract. 2024 Dec 3;12(Suppl 1):i19-i25. doi:
10.1093/nop/npae112. PMID:
39776526. Review. ˍ
Roth P, Capper D, Calabrese E, Halasz LM, Jakola AS.
Role
of the tumor board when
prescribing mutant isocitrate dehydrogenase inhibitors to patients
with isocitrate
dehydrogenase-mutant glioma.
Neurooncol
Pract. 2024 Dec 4;12(Suppl 1):i29-i37. doi:
10.1093/nop/npae100. PMID:
39776528. Review. ˍ